UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

13-5315170

(State of Incorporation)

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.05 par value

PFE

New York Stock Exchange

0.000% Notes due 2020

PFE20A

New York Stock Exchange

0.250% Notes due 2022

PFE22

New York Stock Exchange

1.000% Notes due 2027

PFE27

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

At August 5, 2019, 5,531,048,353 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended June 30, 2019 and July 1, 2018

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2019 and

July 1, 2018

Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018

Condensed Consolidated Statements of Equity for the three and six months ended June 30, 2019 and July 1, 2018

Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and July 1, 2018

10

Notes to Condensed Consolidated Financial Statements

11

Review Report of Independent Registered Public Accounting Firm

46

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

47

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

107

Item 4.

Controls and Procedures

107

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

108

Item 1A.

Risk Factors

108

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

109

Item 3.

Defaults Upon Senior Securities

109

Item 4.

Mine Safety Disclosures

109

Item 5.

Other Information

109

Item 6.

Exhibits

110

Signature

111

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2018 Financial Report

Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018

2018 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2018

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

Allogene Therapeutics, Inc.

Anacor

Anacor Pharmaceuticals, Inc.

AOCI

Accumulated Other Comprehensive Income

Array

Array BioPharma Inc.

Astellas

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

Bamboo

Bamboo Therapeutics, Inc.

Biopharma

Pfizer Biopharmaceuticals Group

BMS

Bristol-Myers Squibb Company

BRCA

BReast CAncer susceptibility gene

CAR T

chimeric antigen receptor T cell

CDC

U.S. Centers for Disease Control and Prevention

cGMP

current Good Manufacturing Practices

Citibank

Citibank, N.A.

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and

New Zealand

EGFR

epidermal growth factor receptor

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),

Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey

EPS

earnings per share

EU

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development organization

GSK

GlaxoSmithKline plc

GS&Co.

Goldman, Sachs & Co. LLC

hGH-CTP

human growth hormone

HIS

Hospira Infusion Systems

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

J&J

Johnson & Johnson

King

King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LDL

low density lipoprotein

LEP

Legacy Established Products

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCC

Merkel cell carcinoma

MCO

managed care organization

mCRC

metastatic colorectal cancer

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation LLC (formerly Medivation, Inc.)

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

Mylan

Mylan N.V.

NDA

new drug application

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PARP

poly ADP ribose polymerase

PBM

pharmacy benefit manager

Pharmacia

Pharmacia Corporation

PP&E

property, plant & equipment

PsA

psoriatic arthritis

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019

RA

rheumatoid arthritis

RCC

renal cell carcinoma

R&D

research and development

ROU

right of use

Sandoz

Sandoz, Inc., a division of Novartis AG

SEC

U.S. Securities and Exchange Commission

SFJ

SFJ Pharmaceuticals Group

Shire

Shire International GmbH

SI&A

selling, informational and administrative

S&P

Standard and Poor s

TCJA

legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Therachon

Therachon Holding AG

UC

ulcerative colitis

U.K.

United Kingdom

U.S.

United States

ViiV

ViiV Healthcare Limited

WRDM

Worldwide Research, Development and Medical

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

June 30,

2019

July 1,

2018

June 30,

2019

July 1,

2018

Revenues

13,264

13,466

26,382

26,373

Costs and expenses:

Cost of sales(a)

2,576

2,916

5,009

5,479

Selling, informational and administrative expenses(a)

3,511

3,542

6,850

6,954

Research and development expenses(a)

1,842

1,797

3,544

3,540

Amortization of intangible assets

1,184

1,191

2,367

2,387

Restructuring charges and certain acquisition-related costs

(115

44

(69

87

Other (income)/deductions net

126

(551

218

(728

Income from continuing operations before provision/(benefit) for taxes on income

4,141

4,527

8,463

8,654

Provision/(benefit) for taxes on income

(915

648

(481

1,204

Income from continuing operations

5,056

3,879

8,945

7,450

Discontinued operations net of tax

(1

Net income before allocation to noncontrolling interests

5,056

3,879

8,945

7,449

Less: Net income attributable to noncontrolling interests

10

15

16

Net income attributable to Pfizer Inc.

5,046

3,872

8,929

7,432

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.91

0.66

1.59

1.26

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.91

0.66

1.59

1.26

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.89

0.65

1.56

1.24

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.89

0.65

1.56

1.24

Weighted-average shares basic

5,562

5,866

5,598

5,911

Weighted-average shares diluted

5,672

5,952

5,711

6,004

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS OF DOLLARS)

June 30,

2019

July 1,

2018

June 30,

2019

July 1,

2018

Net income before allocation to noncontrolling interests

5,056

3,879

8,945

7,449

Foreign currency translation adjustments, net

(485

(699

(161

59

Reclassification adjustments

(35

(20

(485

(734

(159

39

Unrealized holding gains/(losses) on derivative financial instruments, net

(176

127

91

13

Reclassification adjustments for (gains)/losses included in net income(a)

(81

310

(343

354

(256

437

(252

367

Unrealized holding gains/(losses) on available-for-sale securities, net

(7

(374

33

(214

Reclassification adjustments for (gains)/losses included in net income(a)

26

143

37

(31

Reclassification adjustments for unrealized gains included in Retained earnings(b)

(462

19

(231

70

(707

Benefit plans: actuarial gains/(losses), net

(4

(57

(4

106

Reclassification adjustments related to amortization

60

61

121

123

Reclassification adjustments related to settlements, net

30

67

Other

41

107

18

21

100

141

137

316

Benefit plans: prior service costs and other, net

(1

(1

Reclassification adjustments related to amortization of prior service costs and other, net

(46

(46

(93

(92

Reclassification adjustments related to curtailments of prior service costs and other, net

(7

(13

Other

(1

(46

(53

(92

(104

Other comprehensive loss, before tax

(669

(440

(296

(88

Tax provision/(benefit) on other comprehensive loss

(59

173

(34

605

Other comprehensive loss before allocation to noncontrolling interests

(610

(613

(262

(693

Comprehensive income before allocation to noncontrolling interests

4,446

3,266

8,683

6,755

Less: Comprehensive income/(loss) attributable to noncontrolling interests

12

(4

13

Comprehensive income attributable to Pfizer Inc.

4,434

3,270

8,669

6,750

(a)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(b)

For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

June 30,

2019

December 31,

2018

(Unaudited)

Assets

Cash and cash equivalents

1,784

1,139

Short-term investments

11,128

17,694

Trade accounts receivable, less allowance for doubtful accounts: 2019 $540; 2018 $541

9,793

8,025

Inventories

8,233

7,508

Current tax assets

3,723

3,374

Other current assets

2,535

2,461

Assets held for sale

9,877

9,725

Total current assets

47,073

49,926

Long-term investments

2,905

2,767

Property, plant and equipment, less accumulated depreciation: 2019 $16,389; 2018 $16,591

13,521

13,385

Identifiable intangible assets, less accumulated amortization

33,024

35,211

Goodwill

53,352

53,411

Noncurrent deferred tax assets and other noncurrent tax assets

1,935

1,924

Other noncurrent assets

4,388

2,799

Total assets

156,199

159,422

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2019 $2,139; 2018 $4,776

10,507

8,831

Trade accounts payable

4,002

4,674

Dividends payable

1,991

2,047

Income taxes payable

1,536

1,265

Accrued compensation and related items

1,875

2,397

Other current liabilities

10,110

10,753

Liabilities held for sale

2,009

1,890

Total current liabilities

32,030

31,858

Long-term debt

36,168

32,909

Pension benefit obligations, net

4,982

5,272

Postretirement benefit obligations, net

1,310

1,338

Noncurrent deferred tax liabilities

3,180

3,700

Other taxes payable

12,421

14,737

Other noncurrent liabilities

6,183

5,850

Total liabilities

96,274

95,664

Commitments and Contingencies

Preferred stock

18

19

Common stock

468

467

Additional paid-in capital

86,963

86,253

Treasury stock

(110,786

(101,610

Retained earnings

94,440

89,554

Accumulated other comprehensive loss

(11,535

(11,275

Total Pfizer Inc. shareholders equity

59,568

63,407

Equity attributable to noncontrolling interests

357

351

Total equity

59,924

63,758

Total liabilities and equity

156,199

159,422

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance, March 31, 2019

466

19

9,358

468

86,635

(3,801

(110,781

93,388

(10,923

58,806

352

59,158

Net income

5,046

5,046

10

5,056

Other comprehensive income/(loss), net of tax

(613

(613

(610

Cash dividends declared:

Common stock

(3,994

(3,994

(3,994

Preferred stock

Noncontrolling interests

(8

(8

Share-based payment transactions

329

(6

324

324

Purchases of common stock

Preferred stock conversions and redemptions

(8

(1

(1

(1

Other

Balance, June 30, 2019

458

18

9,363

468

86,963

(3,801

(110,786

94,440

(11,535

59,568

357

59,924

PFIZER INC. SHAREHOLDERS

Preferred Stock

Common Stock

Treasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated Value

Shares

Par Value

Add l

Paid-In Capital

Shares

Cost

Retained Earnings

Accum. Other Comp.

Loss

Share-

holders Equity

Non-controlling interests

Total Equity

Balance April 1, 2018

513

21

9,299

465

84,599

(3,437

(95,460

89,961

(9,402

70,184

358

70,541

Net income

3,872

3,872

3,879

Other comprehensive income/(loss), net of tax

(602

(602

(11

(613

Cash dividends declared:

Common stock

(3,970

(3,970

(3,970

Preferred stock

Noncontrolling interests

(7